The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway–inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic - 23/07/20
Doi : 10.1016/j.jaad.2020.05.035
Marilyn T. Wan, MBChB, MPH a, Daniel B. Shin, PhD a, Kevin L. Winthrop, MD, MPH b, Joel M. Gelfand, MD, MSCE a, c, ⁎ 
a Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
b Division of Infectious Diseases and Public Health, Oregon Health and Sciences University, Portland, Oregon
c Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
∗Correspondence to: Joel M. Gelfand, MD, MSCE, Department of Dermatology, 3400 Civic Center Blvd, Perelman Center for Advanced Medicine, South Tower, Office 730, Philadelphia, PA, 19104Department of Dermatology3400 Civic Center BlvdPerelman Center for Advanced MedicineSouth Tower, Office 730PhiladelphiaPA19104
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
| Funding sources: Supported in part by a grant (P30-AR0-69589-03) from the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases to Dr Gelfand. |
|
| Conflicts of interest: Dr Gelfand served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (Data Safety and Monitoring Board), Sanofi, and Pfizer Inc, receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Janssen, Novartis Corp, Sanofi, Celgene, Ortho Dermatologics, and Pfizer Inc, and has received payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics. In addition, Dr Gelfand is a copatent holder of resiquimod for treatment of cutaneous T-cell lymphoma, and is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology. Dr Wan is supported in part by a grant from Pfizer. Dr Winthrop receives grants from Bristol-Myers Squibb and Pfizer, and is a consultant for UCB, AbbVie, Eli Lilly and Company, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, and Roche. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 2
P. 677-679 - août 2020 Retour au numéro
Article précédent
- COVID-19 and personal protective equipment: Treatment and prevention of skin conditions related to the occupational use of personal protective equipment
- Seemal R. Desai, Carrie Kovarik, Bruce Brod, William James, Matthew E. Fitzgerald, Ave Preston, George J. Hruza
- Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign”
- Carlos Gustavo Wambier, Sergio Vaño-Galván, John McCoy, Alba Gomez-Zubiaur, Sabina Herrera, Ángela Hermosa-Gelbard, Oscar M. Moreno-Arrones, Natalia Jiménez-Gómez, Alvaro González-Cantero, Pablo Fonda-Pascual, Gonzalo Segurado-Miravalles, Jerry Shapiro, Bibiana Pérez-García, Andy Goren
Bienvenue sur EM-consulte, la référence des professionnels de santé.